[PTLA] Portola Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 25.06 Change: 6.33 (33.8%)
Ext. hours: 24.85 Change: -0.21 (-0.84%)

chart PTLA

Refresh chart

Strongest Trends Summary For PTLA

PTLA is in the medium-term down -13% below S&P in 5 months. In the long-term down -39% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company?s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen t

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -2.28% Sales Growth - Q/Q-2.2% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-31.53% ROE-36.59% ROI
Current Ratio9.89 Quick Ratio Long Term Debt/Equity Debt Ratio0.1
Gross Margin Operating Margin-1592.24% Net Profit Margin-1595.01% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities113.04 M Cash From Investing Activities9.44 M Cash From Operating Activities-47.15 M Gross Profit
Net Profit-46.91 M Operating Profit-46.5 M Total Assets486.3 M Total Current Assets403.45 M
Total Current Liabilities40.79 M Total Debt Total Liabilities67.32 M Total Revenue2.36 M
Technical Data
High 52 week37.76 Low 52 week15.46 Last close30.94 Last change1.91%
RSI68.73 Average true range1.39 Beta1.71 Volume8.33 M
Simple moving average 20 days15.82% Simple moving average 50 days15.78% Simple moving average 200 days14.08%
Performance Data
Performance Week24.76% Performance Month18.27% Performance Quart-2.7% Performance Half8.41%
Performance Year-17.97% Performance Year-to-date58.5% Volatility daily3.23% Volatility weekly7.23%
Volatility monthly14.81% Volatility yearly51.32% Relative Volume1513.75% Average Volume1.04 M
New High New Low

News

2019-08-22 08:30:00 | Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

2019-08-16 11:08:39 | Here's Why Portola Pharmaceuticals NASDAQ:PTLA Can Afford Some Debt

2019-08-13 19:32:00 | Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock

2019-08-13 07:25:15 | The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results

2019-08-12 16:43:00 | Portola Pharmaceuticals Announces Proposed Offering of Common Stock

2019-08-08 16:15:00 | Why Portola Pharmaceuticals Is Rocketing 10.9% Higher Today

2019-08-08 01:31:18 | Edited Transcript of PTLA earnings conference call or presentation 7-Aug-19 8:30pm GMT

2019-08-07 21:24:06 | Portola Pharmaceuticals Inc PTLA Q2 2019 Earnings Call Transcript

2019-08-07 18:25:10 | Portola Pharmaceuticals PTLA Reports Q2 Loss, Tops Revenue Estimates

2019-08-07 16:05:00 | Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

2019-08-07 11:20:03 | Bausch BHC Misses on Q2 Earnings & Sales, Raises View

2019-08-07 11:15:03 | Endo ENDP Q2 Earnings & Revenues Beat Estimates, Down Y/Y

2019-08-07 08:42:12 | Zoetis ZTS Looks Good: Stock Adds 7.6% in Session

2019-08-06 10:51:02 | Zoetis ZTS Beats on Earnings in Q2, Lifts 2019 Guidance

2019-08-06 08:30:00 | Portola Launches European Sales of Ondexxya® Andexanet Alfa with First Orders in Europe

2019-08-05 07:00:00 | U.S. Centers for Medicare and Medicaid Services CMS Increases New Technology Add-On Payment NTAP Reimbursement for Portola Pharmaceuticals' Andexxa

2019-07-31 10:36:02 | Portola Pharmaceuticals PTLA May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-07-17 08:30:00 | Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

2019-07-08 08:30:00 | Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates 4F-PCCs Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors

2019-06-19 11:05:00 | Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

2019-06-18 08:04:49 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-06-13 08:03:31 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-06-11 08:04:20 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-06-10 08:02:23 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-06-08 08:09:16 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-06-04 08:04:30 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-05-28 16:30:00 | Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

2019-05-24 09:00:17 | What’s Portola’s Growth Strategy for Fiscal 2019?

2019-05-24 07:30:43 | How Is Portola’s Andexxa Placed in the First Quarter?

2019-05-22 10:45:00 | Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous Non-Traumatic Intracranial Hemorrhage

2019-05-09 08:16:00 | 3 Key Takeaways From Portola Pharmaceuticals' Quarterly Results

2019-05-08 22:18:13 | Edited Transcript of PTLA earnings conference call or presentation 8-May-19 12:30pm GMT

2019-05-08 14:23:45 | Portola Pharmaceuticals Inc PTLA Q1 2019 Earnings Call Transcript

2019-05-08 13:10:00 | Why Portola Pharmaceuticals Is Tumbling 14.5% Today

2019-05-08 09:25:01 | Portola Pharmaceuticals PTLA Reports Q1 Loss, Tops Revenue Estimates

2019-05-08 08:19:33 | Portola Pharmaceuticals: 1Q Earnings Snapshot

2019-05-08 08:01:00 | Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-08 06:30:00 | Portola Pharmaceuticals, Inc. to Host Earnings Call

2019-05-07 08:06:01 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-05-02 14:39:49 | Did Hedge Funds Drop The Ball On Portola Pharmaceuticals Inc PTLA?

2019-05-01 10:32:02 | Portola Pharmaceuticals PTLA May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-04-26 14:00:47 | European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ andexanet alfa, the First and Only Antidote for the Reversal of Factor Xa Inhibitors

2019-04-24 08:30:00 | Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development

2019-04-17 16:15:00 | Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019

2019-04-12 12:01:00 | Portola Pharmaceuticals: Is It Still a Buy?

2019-04-09 10:48:23 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

2019-03-26 17:32:59 | Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote

2019-03-25 09:19:13 | Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more

2019-03-21 06:30:00 | HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results

2019-03-20 17:00:00 | Portola Pharmaceuticals’ Co-Founder Dr. Charles Homcy Retires from the Company’s Board of Directors